Cumberland Pharmaceuticals Inc.
NASDAQ:CPIX · NASDAQ Global Select
-$0.06 today
Vol 0.03M · Avg 0.97M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$2.9M +55.8% | -$6.5M -3.2% | -$6.3M -11.1% | -$5.7M -56.8% | -$3.6M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $5.3M -12.5% | $6.0M +4.7% | $5.8M +8.3% | $5.3M +15.7% | $4.6M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 +100.0% | -$192.8K | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $408.3K +35.3% | $301.9K -17.3% | $365.0K -18.4% | $447.5K -39.7% | $741.9K | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $2.2M +67.3% | $1.3M -72.1% | $4.6M -57.8% | $11.0M +34.1% | $8.2M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$5.2M -169.8% | -$1.9M -157.1% | $3.4M +155.7% | -$6.1M -211.2% | $5.5M | $592.6M | $1.3B | $626.2M |
| Inventory | $2.2M -6.9% | $2.4M +10506.6% | -$23.1K -101.7% | $1.4M -71.5% | $4.8M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $6.7M +776.8% | -$991.4K -126.6% | $3.7M -75.3% | $15.1M +2088.9% | -$757.6K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$1.5M -184.9% | $1.8M +173.6% | -$2.5M -483.2% | $644.9K +146.8% | -$1.4M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$60.0K +96.6% | -$1.8M -210.5% | $1.6M +160.6% | -$2.6M +22.0% | -$3.4M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $4.9M +905.7% | -$612.2K -110.0% | $6.1M -27.9% | $8.5M +33.3% | $6.3M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$97.9K +45.5% | -$179.7K +60.3% | -$453.1K +78.2% | -$2.1M -485.1% | -$354.5K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 +100.0% | -$13.5M | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$4.5M | $0 | $0 | $0 +100.0% | -$200.0K | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$47.0K -119.8% | $237.6K -31.6% | $347.4K -81.7% | $1.9M +3513.1% | $52.6K | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$4.7M -8236.8% | $57.8K +154.7% | -$105.7K +99.2% | -$13.7M -2624.6% | -$501.9K | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$10.0M -502.7% | $2.5M +173.0% | -$3.4M -384.7% | $1.2M | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $5.3M | $0 | $0 | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$263.5K +54.5% | -$579.0K +21.8% | -$740.5K +29.7% | -$1.1M +24.1% | -$1.4M | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$1.7M +0.2% | -$1.7M +47.5% | -$3.3M -48.0% | -$2.2M -1.9% | -$2.2M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$6.7M -3525.8% | $196.9K +102.7% | -$7.4M -260.1% | -$2.1M +42.0% | -$3.6M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$6.5M -1723.9% | -$357.4K +75.1% | -$1.4M +80.3% | -$7.3M -418.4% | $2.3M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $4.8M +710.5% | -$791.9K -114.0% | $5.6M -11.6% | $6.4M +6.5% | $6.0M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Lantern Pharma Inc.
NASDAQ:LTRN
$47.34M
LAVA Therapeutics N.V.
LVTX
$45.77M
Dyadic International, Inc.
DYAI
$29.28M
Rockwell Medical, Inc.
RMTI
$25.90M
ABVC BioPharma, Inc.
ABVC
$19.28M
Celularity Inc.
CELU
$18.08M
Quantum BioPharma Ltd.
QNTM
$16.90M
CalciMedica, Inc.
CALC
$11.93M
Inotiv, Inc.
NOTV
$2.79M
Reviva Pharmaceuticals Holdings, Inc.
RVPH
$2.05M
SEC Filings
Recent regulatory filings
No filings found.
Does CPIX generate free cash flow?
Cumberland Pharmaceuticals Inc. (CPIX) generated $4.83M of free cash flow in fiscal 2025.
How much operating cash flow does CPIX produce?
Operating cash flow was $4.93M, before capital expenditures of $97,902.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.